| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-07-01 | Sanofi-aventis (France) Juvenile Diabetes Research Foundation (JDRF – USA) |
immune therapies, beta cell regeneration / type 1 diabetes | R&D other |
See details |
| 2010-07-01 | X-Chem (USA) Roche (Switzerland) |
R&D |
See details | |
| 2010-06-30 | OctoPlus (The Netherlands) Novartis (Switzerland) |
controlled release formulation of an undisclosed compound | R&D other |
See details |
| 2010-06-30 | TargeGen (USA) Sanofi-aventis (France) |
inhibitor of Janus kinase 2 (JAK-2) and additional tyrosine kinases / hematological cancers, blood disorders | other |
See details |
| 2010-06-28 | Marinomed Biotechnologie (Austria) Boehringer Ingelheim (Germany) |
anti-viral nasal spray based on Marinomed’s anti-viral respiratory technology platform mavirex |
licensing |
See details |
| 2010-06-25 | Metabolex (USA) Sanofi-Aventis (France) |
small molecules that modulate the G-protein coupled receptor 119 (GPR119), including an orally active GPR119 agonist, MBX-2982 / Type 2 Diabetes |
R&D manufacturing commercialization/ distribution development |
See details |
| 2010-06-22 | Regulus Therapeutics (USA) Sanofi-Aventis (France) |
microRNA therapeutics (micro RNA are small - typically 20 to 25 nucleotides in length- non-coding RNAs that regulate gene expression by interfering with translation or stability of target messenger RNA transcripts) / fibrosis |
R&D commercialization/ distribution |
See details |
| 2010-06-22 | Diamyd Medical (Sweden) Ortho-McNeil-Janssen Pharmaceuticals (J&J company – USA) |
GAD65 antigen-based therapy (Diamyd®) / treatment and prevention of type 1 diabetes and associated conditions |
commercialization/ distribution development |
See details |
| 2010-06-17 | Drug Safety Executive Council (USA) Biocortech (France) |
other |
See details | |
| 2010-06-17 | Neurocrine Biosciences (USA) Boehringer Ingelheim (Germany) |
small molecule GPR119 agonists (GPR119 is a G-protein coupled receptor that has been implicated as a novel target for the treatment of Type 2 diabetes. The activation of GPR119 receptors located in the digestive system stimulates incretins, resulting in increased insulin production, while activation of GPR119 receptors located on pancreatic islet beta cells also stimulates insulin secretion). / Type 2 diabetes |
R&D |
See details |
| 2010-06-17 | OncoMed Pharmaceuticals (USA) Bayer Schering Pharma (Germany) |
anti-cancer stem cell therapeutics (small molecules, antibody and protein therapeutic products) targeting the Wnt signaling pathway. This pathway is a therapeutic target in halting cancer stem cell activity. / cancer | R&D commercialization/ distribution development |
See details |
| 2010-06-17 | Qiagen (Germany) Genome Diagnostics (The Netherlands) |
molecular tests targeting the detection of genetic variations in the HLA complex. / prevention and personalized healthcare |
commercialization/ distribution development |
See details |
| 2010-06-16 | Oncodesign (France), Janssen Pharmaceutica (Belgium - Johnson&Johnson company |
macrocyclic chemistry technology / cancer |
licensing |
See details |
| 2010-06-15 | Vivalis (France) undisclosed animal health company |
EB66® cell line | licensing |
See details |
| 2010-06-15 | Talecris Biotherapeutics (USA) Novartis Vaccines (USA – Switzerland) |
post-exposure rabies products / rabies |
marketing/ promotion |
See details |
